MarginsXMarginsX
Home › Data Desk › Gossamer Bio Inc. revenue rises 189.1% in the quarter to Sep 30, 2026

MarginsX Data Desk · Quarterly results · Reverse split · FDA approval · Private placement (PIPE)

Gossamer Bio Inc. revenue rises 189.1% in the quarter to Sep 30, 2026

Gossamer Bio Inc. (GOSS) filed its 10-Q on Nov 10, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 10, 2026.

Bar chart of Gossamer Bio Inc.'s quarterly revenue from Dec 31, 2024 to Sep 30, 2026, the latest quarter highlighted.

Revenue and margins

Revenue was $38.4M, up 189.1% from $13.3M in the same period a year earlier, which ended Sep 30, 2025. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

The net loss was $48.1M. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

Balance sheet

Cash was $51.2M at Sep 30, 2026, against $41.1M at Jun 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

Total debt was $37.1M, against $36.1M at Jun 30, 2026. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

Shares outstanding were 6.1 million, against 488.8 million at Jun 30, 2026, a fall of 98.7%. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

At its recent quarterly burn of $39.0M, that cash lasts about 3.9 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

The stock

The Nasdaq screener puts its market value at $68.7M. (Nasdaq stock screener, Nov 13, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/GOSS)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NameGossamer Bio Inc.Source2026-11-13
Revenue change1.891 %Source2026-11-10
Revenue38,431,000 USDSource2026-11-10
Revenue a year earlier13,294,000 USDSource2026-11-10
Period endSep 30, 2026Source2026-11-10
WhoGossamer Bio Inc. (GOSS)Source2026-11-13
SymbolGOSSSource2026-11-13
Form10-QSource2026-11-10
FiledNov 10, 2026Source2026-11-10
A year earlier endSep 30, 2025Source2026-11-10
Net loss48,072,000 USDSource2026-11-10
Net income-48,072,000 USDSource2026-11-10
Cash51,189,000 USDSource2026-09-30
Cash prior41,148,000 USDSource2026-08-13
Prior endJun 30, 2026Source2026-08-13
Debt37,150,000 USDSource2026-11-10
Debt prior36,145,000 USDSource2026-08-13
Shares6,116,390 sharesSource2026-11-10
Shares prior488,846,722 sharesSource2026-08-13
Dilution-0.987 %Source2026-11-10
Burn abs39,009,500 USDSource2026-09-30
Burn-39,009,500 USDSource2026-09-30
Runway3.9 monthsSource2026-09-30
Cap68,748,224 USDSource2026-11-13

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS